Tumor Models Market Report 2026

Tumor Models Market Overview

• Tumor Models market size has reached to $2.13 billion in 2025 • Expected to grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 10.8% • Growth Driver: Growing Demand For Personalized Medicine Shaping The Market Growth Due To People Preferring Health Technologies • Market Trend: Advancements In 3D Tumor Modeling For Improved Predictive Accuracy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tumor Models Market?

Tumor models are experimental biological systems created to imitate the features and behavior of tumors found in living organisms. They are structured to reflect the cellular composition, molecular traits, and growth patterns of cancer, as well as its interaction with the surrounding environment. Such models allow researchers to study tumor formation and progression in a controlled setting, supporting a deeper understanding of cancer biology. The main types of tumor models are primary tumor models, metastatic tumor models, orthotopic tumor models, and heterotopic tumor models. Primary tumor models refer to experimental tumor models developed by implanting or inducing cancer cells at the original site where the tumor naturally arises in the body. The multiple applications involved are drug discovery and development, cancer research, personalized medicine, and toxicology studies, and it uses various technologies, including xenograft models, genetically engineered mouse models (GEMMs), three-dimensional (3D) tumor spheroids, and organ-on-a-chip models. It caters to several end users, such as pharmaceutical and biotechnology companies, academic institutions, contract research organizations (CROs), and government research organizations.

What Is The Tumor Models Market Growth Forecast?

The tumor models market size is expected to see rapid growth in the next few years. It will grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to advancements in organ-on-a-chip and 3d spheroid technologies, increasing focus on personalized oncology treatments, expansion of contract research organizations (cros) in tumor research, rising pharmaceutical R&D expenditure, integration of ai and big data analytics in tumor model studies. Major trends in the forecast period include increasing use of 3d tumor spheroids and organ-on-a-chip models, rising demand for personalized medicine and targeted cancer therapies, expansion of xenograft and genetically engineered mouse models (gemms), growth in drug discovery and toxicology studies using tumor models, collaboration between pharmaceutical companies and academic institutions.

Global Tumor Models Market Segmentation

1) By Type Of Tumor: Primary Tumor Models, Metastatic Tumor Models, Orthotopic Tumor Models, Heterotopic Tumor Models 2) By Application: Drug Discovery And Development, Cancer Research, Personalized Medicine, Toxicology Studies 3) By Technology: Xenograft Models, Genetically Engineered Mouse Models (GEMMs), Three-Dimensional (3D) Tumor Spheroids, Organ-On-A-Chip Models 4) By End-User: Pharmaceutical And Biotechnology Companies, Academic Institutions, Contract Research Organizations (CROs), Government Research Organizations Subsegments: 1) By Primary Tumor Models: Carcinoma Models, Sarcoma Models, Glioma Models, Melanoma Models, Leukemia Models, Lymphoma Models 2) By Metastatic Tumor Models: Lung Metastasis Models, Bone Metastasis Models, Liver Metastasis Models, Brain Metastasis Models, Lymph Node Metastasis Models 3) By Orthotopic Tumor Models: Orthotopic Breast Cancer Models, Orthotopic Lung Cancer Models, Orthotopic Pancreatic Cancer Models, Orthotopic Colon Cancer Models, Orthotopic Prostate Cancer Models 4) By Heterotopic Tumor Models: Subcutaneous Tumor Models, Intramuscular Tumor Models, Intraperitoneal Tumor Models

What Is The Driver Of The Tumor Models Market?

The growing demand for personalized medicine is expected to propel the growth of the tumor models market going forward. Personalized medicine refers to a medical model that uses information about a person’s genes and lifestyle environment to tailor treatments and healthcare to their specific needs. The rise of personalized medicine is due to people preferring health technologies that offer real-time monitoring and treatment plans customized to their unique biology. Tumor models help personalized medicine by allowing researchers and clinicians to test and predict how individual patients' tumors will respond to specific treatments as experimental platforms that mimic the behavior of real human cancers, enabling a more tailored approach to therapy. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the growing demand for personalized medicine is driving the growth of the tumor models industry.

Key Players In The Global Tumor Models Market

Major companies operating in the tumor models market are WuXi AppTec Co Ltd., Charles River Laboratories International Inc., Pharmaron Beijing Co. Ltd., The Jackson Laboratory, Taconic Biosciences Inc., Cyagen Biosciences Inc., Crown Bioscience Inc., Champions Oncology Inc., InSphero AG, Creative Biolabs Inc., Oncodesign S.A., Xentech S.A., MIMETAS BV, Experimental Pharmacology and Oncology Berlin-Buch GmbH.

Global Tumor Models Market Trends and Insights

Major companies operating in the tumor models market are focusing on developing advanced solutions, such as tumor spheroid models, to enhance the physiological relevance and predictive accuracy of in vitro cancer models. Tumor spheroid models refer to three-dimensional (3D) aggregates of cancer cells that spontaneously form spherical structures in culture. For instance, in June 2024, Predictive Oncology, a US-based provider of advanced 3D cell culture technologies and predictive oncology solutions, launched novel 3D cell technology to accelerate cancer therapeutic drug discovery. It offers unique features such as advanced 3D tumor spheroid and organoid models that closely mimic the tumor microenvironment, high-throughput screening capabilities for rapid drug testing, support for patient-derived personalized tumor models, detailed analysis of drug penetration in 3D structures, and integration with AI-driven data analytics for enhanced predictive accuracy and deeper insights into therapeutic responses.

What Are Latest Mergers And Acquisitions In The Tumor Models Market?

In October 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Modifi Biosciences for an undisclosed amount. Through this acquisition, Merck aims to strengthen its oncology portfolio by integrating Modifi’s novel small-molecule therapies designed to selectively target cancer cells deficient in the deoxyribonucleic acid (DNA) repair with a focus on hard-to-treat tumors such as glioblastomas. Modifi Biosciences Inc. is a US-based biotechnology company that specializes in tumor models.

Regional Insights

North America was the largest region in the tumor models market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tumor Models Market?

The tumor models market includes revenues earned by entities by providing services such as drug screening and efficacy testing, tumor biology research, biomarker discovery and validation, toxicology and safety testing, and immuno-oncology studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor models market also includes sales of cancer cell lines, in vitro tumor models, imaging systems, tumor model kits, and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tumor Models Market Report 2026?

The tumor models market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tumor models industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.